The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung ca...
Saved in:
| Published in | Frontiers in oncology Vol. 15; p. 1578419 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
02.07.2025
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC).
This retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC).
SUR-L exhibited the highest diagnostic accuracy (AUC = 0.758,
< 0.001). Among 30 immunotherapytreated patients, PD-L1 positivity and SUR-BP ≥ 7.30 were associated with prolonged disease-free survival (DFS) (
= 0.012 and
= 0.035, respectively).
Our findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment. |
|---|---|
| AbstractList | Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC).
This retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC).
SUR-L exhibited the highest diagnostic accuracy (AUC = 0.758,
< 0.001). Among 30 immunotherapytreated patients, PD-L1 positivity and SUR-BP ≥ 7.30 were associated with prolonged disease-free survival (DFS) (
= 0.012 and
= 0.035, respectively).
Our findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment. IntroductionTotal-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC). MethodsThis retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC). ResultsSUR-L exhibited the highest diagnostic accuracy (AUC = 0.758, p < 0.001). Among 30 immunotherapytreated patients, PD-L1 positivity and SUR-BP ≥ 7.30 were associated with prolonged disease-free survival (DFS) (p = 0.012 and p = 0.035, respectively).DiscussionOur findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment. Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC).IntroductionTotal-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing programmed death ligand 1 (PD-L1) expression heterogeneity between primary tumors (PTs) and metastatic tumors (MTs) in advanced nonsmall cell lung cancer (NSCLC).This retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC).MethodsThis retrospective study of 99 treatment-naïve NSCLC patients revealed that metabolic parameters (SUVmax, SUR-L, and SUR-BP) derived from biopsy-correlated PET/CT sites significantly predicted high PD-L1 expression (TC ≥ 50% or IC ≥ 10% by IHC).SUR-L exhibited the highest diagnostic accuracy (AUC = 0.758, p < 0.001). Among 30 immunotherapytreated patients, PD-L1 positivity and SUR-BP ≥ 7.30 were associated with prolonged disease-free survival (DFS) (p = 0.012 and p = 0.035, respectively).ResultsSUR-L exhibited the highest diagnostic accuracy (AUC = 0.758, p < 0.001). Among 30 immunotherapytreated patients, PD-L1 positivity and SUR-BP ≥ 7.30 were associated with prolonged disease-free survival (DFS) (p = 0.012 and p = 0.035, respectively).Our findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment.DiscussionOur findings establish SUR-BP as a novel non-invasive biomarker for immunotherapy prognosis in NSCLC, addressing spatial heterogeneity challenges in PD-L1 assessment. |
| Author | Xuan, Ang Jin, Huibin Xu, Junling Gao, Yongju Wu, Xinyu Zhang, Jie Hu, Bingxin Long, Ye |
| AuthorAffiliation | 1 Department of Nuclear Medicine of Henan Provincial People’s Hospital and The People’s Hospital of Zhengzhou University , Zhengzhou , China 2 Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People’s Hospital , Zhengzhou , China |
| AuthorAffiliation_xml | – name: 2 Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Henan Provincial People’s Hospital , Zhengzhou , China – name: 1 Department of Nuclear Medicine of Henan Provincial People’s Hospital and The People’s Hospital of Zhengzhou University , Zhengzhou , China |
| Author_xml | – sequence: 1 givenname: Huibin surname: Jin fullname: Jin, Huibin – sequence: 2 givenname: Bingxin surname: Hu fullname: Hu, Bingxin – sequence: 3 givenname: Jie surname: Zhang fullname: Zhang, Jie – sequence: 4 givenname: Ye surname: Long fullname: Long, Ye – sequence: 5 givenname: Ang surname: Xuan fullname: Xuan, Ang – sequence: 6 givenname: Xinyu surname: Wu fullname: Wu, Xinyu – sequence: 7 givenname: Junling surname: Xu fullname: Xu, Junling – sequence: 8 givenname: Yongju surname: Gao fullname: Gao, Yongju |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40672750$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkstu1DAUhiNURC_0AdggL9lk6lsuXiE0LaXSSHQxSOwsxz6euErsYCcjZs-DkzBD1XphW-f85zu-_JfZmQ8esuwDwSvGanFjg9crimmxIkVVcyLeZBeUMp4Lzn6evdifZ9cpPeF5lAUmmL3LzjkuK1oV-CL7s20BDRGM06PbA9qrbgIULBrDqDrUBHNAj3fbm_UWOY9at2vR422-IQh-z1UpueCR8ga5vp98GFuIajgsUmX2ymswaD52nnrVdUjDPHWT3yG9pCIa1OjAj-l99taqLsH1ab3Kfny9266_5Zvv9w_rL5tcM16PuaCWWFxjbKAmgAmHhlSgqbGVpoqxhgMtG0rK2pZW0Dkkam1BcGKMqgrOrrKHI9cE9SSH6HoVDzIoJ_8FQtxJFUenO5BWW0J1XZbWlJzqQnAAqjCtDWtModXM-nxkDVPTg9HzPaLqXkFfZ7xr5S7sJaG0ZByLmfDpRIjh1wRplL1LyxspD2FKklGGBWGYk1n68WWz5y7__3EWkKNAx5BSBPssIVgudpGLXeRiF3myC_sL_cK00w |
| Cites_doi | 10.1007/s00262-019-02387-9 10.1016/S1470-2045(16)30624-6 10.3389/fonc.2022.943933 10.1016/S0140-6736(18)32409-7 10.1136/jitc-2020-002230 10.1007/s00262-020-02560-5 10.1038/s41598-020-71735-y 10.1016/S0140-6736(15)01281-7 10.1186/s40364-017-0093-8 10.1016/j.cllc.2018.02.008 10.1038/nrc.2016.36 10.1016/j.ejca.2018.06.022 10.1097/MNM.0000000000000832 10.1093/annonc/mdv489 10.1016/j.lungcan.2018.03.001 10.1016/j.jtho.2022.04.012 10.3390/life13041051 10.1016/j.bbrc.2018.03.053 10.3390/cancers14246095 10.1016/S0140-6736(16)32517-X 10.1007/s00259-021-05462-5 10.1007/s00259-016-3425-2 10.1186/2191-219X-4-18 10.1093/annonc/mdw289 10.18632/oncotarget.18257 10.7150/jca.63003 10.1186/2191-219X-3-77 10.1371/journal.pone.0186192 10.21037/jtd.2020.04.45 10.1007/s12149-020-01451-0 10.1007/s00259-019-04500-7 10.1097/MNM.0000000000001136 10.3389/fmed.2022.895401 10.1007/s00259-017-3806-1 10.21873/anticanres.11813 10.1016/S0140-6736(16)00587-0 10.1038/s41379-021-00903-w 10.2147/CMAR.S256871 10.2967/jnumed.116.184028 10.1002/cam4.1215 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao. Copyright © 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao |
| Copyright_xml | – notice: Copyright © 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao. – notice: Copyright © 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fonc.2025.1578419 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2234-943X |
| ExternalDocumentID | oai_doaj_org_article_fcf12c866fd642c594ee2a028d3bd5ca PMC12263409 40672750 10_3389_fonc_2025_1578419 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M~E OK1 PGMZT RNS RPM IPNFZ M48 NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c348t-92f1f0800de81e014eb17ec2df7c2a33b4e26b2168f6f922a398cfe941dda7543 |
| IEDL.DBID | DOA |
| ISSN | 2234-943X |
| IngestDate | Wed Aug 27 01:32:28 EDT 2025 Thu Aug 21 18:22:31 EDT 2025 Thu Jul 17 18:30:34 EDT 2025 Sun Jul 20 01:30:46 EDT 2025 Thu Jul 10 07:26:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | PD-L1 SUR NSCLC prognosis immunotherapy |
| Language | English |
| License | Copyright © 2025 Jin, Hu, Zhang, Long, Xuan, Wu, Xu and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c348t-92f1f0800de81e014eb17ec2df7c2a33b4e26b2168f6f922a398cfe941dda7543 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Ganesh Kumar Barik, Dana–Farber Cancer Institute, United States Reviewed by: Bharath Kumar Gajjela, Icahn School of Medicine at Mount Sinai, United States These authors have contributed equally to this work Edited by: Balkrishna Chaube, Indian Institute of Technology Dharwad, India |
| OpenAccessLink | https://doaj.org/article/fcf12c866fd642c594ee2a028d3bd5ca |
| PMID | 40672750 |
| PQID | 3230913041 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fcf12c866fd642c594ee2a028d3bd5ca pubmedcentral_primary_oai_pubmedcentral_nih_gov_12263409 proquest_miscellaneous_3230913041 pubmed_primary_40672750 crossref_primary_10_3389_fonc_2025_1578419 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-02 |
| PublicationDateYYYYMMDD | 2025-07-02 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in oncology |
| PublicationTitleAlternate | Front Oncol |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Hellmann (B3) 2017; 18 Hu (B22) 2020 Kian (B15) 2020; 12 Chao Li (B19) 2017 Zhang (B41) 2022; 17 Herbst (B5) 2016; 387 Cherry (B20) 2018; 59 Kasahara (B34) 2018; 119 Wang (B35) 2020; 47 (B9) 2016 Kudura (B40) 2022; 14 Takamori (B11) 2017; 37 Kaira (B32) 2018; 101 Malet (B39) 2023; 13 Moutafi (B16) 2021; 9 Xiao (B21) 2021; 49 Yang (B25) 2021; 12 Nakamura (B10) 2017; 12 Hu (B23) 2020; 41 (B8) 2021 Zhang (B33) 2017; 8 Kaira (B37) 2018; 45 van den Hoff (B30) 2013; 3 Tien Cong (B31) 2022; 9 van den Hoff (B29) 2014; 4 Diggs (B7) 2017; 5 Grizzi (B36) 2019; 68 Mansfield (B12) 2016; 27 Topalian (B6) 2016; 16 Mitchell (B27) 2020; 69 Fehrenbacher (B1) 2016; 387 Cui (B42) 2020; 12 Ilie (B14) 2016; 27 Wu (B18) 2022; 35 Lopci (B26) 2016; 43 Hu (B24) 2022; 12 Mok (B4) 2019; 393 Yamaguchi (B43) 2020; 10 Zhou (B13) 2018; 498 Takada (B28) 2017; 6 Castello (B38) 2018; 39 Liu (B17) 2018; 19 Rittmeyer (B2) 2017; 389 |
| References_xml | – volume: 68 year: 2019 ident: B36 article-title: Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-019-02387-9 – volume: 18 start-page: 31 year: 2017 ident: B3 article-title: Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30624-6 – volume: 12 year: 2022 ident: B24 article-title: The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression publication-title: Front Oncol doi: 10.3389/fonc.2022.943933 – volume: 393 year: 2019 ident: B4 article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32409-7 – volume: 9 year: 2021 ident: B16 article-title: Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer publication-title: J ImmunoTherapy Cancer doi: 10.1136/jitc-2020-002230 – volume: 69 year: 2020 ident: B27 article-title: 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02560-5 – year: 2017 ident: B19 article-title: Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer publication-title: J Thorac Oncol – volume-title: TECENTRIQ ® (Atezolizumab) Injection, for Intravenous Use Initial U.S. Approval: 2016. Reference ID: 4748227 year: 2016 ident: B9 – volume: 10 year: 2020 ident: B43 article-title: Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% publication-title: Sci Rep-UK doi: 10.1038/s41598-020-71735-y – volume: 387 year: 2016 ident: B5 article-title: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01281-7 – volume: 5 year: 2017 ident: B7 article-title: Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response publication-title: Biomarker Res doi: 10.1186/s40364-017-0093-8 – volume: 19 year: 2018 ident: B17 article-title: Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2018.02.008 – volume: 16 year: 2016 ident: B6 article-title: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy publication-title: Nat Rev Cancer doi: 10.1038/nrc.2016.36 – volume: 101 year: 2018 ident: B32 article-title: 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.06.022 – volume: 39 year: 2018 ident: B38 article-title: Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer publication-title: Nucl Med Commun doi: 10.1097/MNM.0000000000000832 – volume: 27 year: 2016 ident: B14 article-title: Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies publication-title: Ann Oncol doi: 10.1093/annonc/mdv489 – volume: 119 year: 2018 ident: B34 article-title: Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma publication-title: Lung Cancer doi: 10.1016/j.lungcan.2018.03.001 – volume: 17 year: 2022 ident: B41 article-title: Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2022.04.012 – volume: 13 year: 2023 ident: B39 article-title: Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC publication-title: Life doi: 10.3390/life13041051 – volume: 498 year: 2018 ident: B13 article-title: Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer publication-title: Biochem Bioph Res Co doi: 10.1016/j.bbrc.2018.03.053 – volume: 14 year: 2022 ident: B40 article-title: Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors publication-title: Cancers doi: 10.3390/cancers14246095 – volume: 389 year: 2017 ident: B2 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X – volume: 49 year: 2021 ident: B21 article-title: Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by 18F-FDG total-body PET/CT imaging publication-title: Eur J Nucl Med Mol I doi: 10.1007/s00259-021-05462-5 – volume: 43 year: 2016 ident: B26 article-title: Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery publication-title: Eur J Nucl Med Mol I doi: 10.1007/s00259-016-3425-2 – volume: 4 year: 2014 ident: B29 article-title: Correction of scan time dependence of standard uptake values in oncological PET publication-title: EJNMMI Res doi: 10.1186/2191-219X-4-18 – volume: 27 year: 2016 ident: B12 article-title: Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdw289 – volume: 8 year: 2017 ident: B33 article-title: Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.18257 – volume: 12 year: 2021 ident: B25 article-title: PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study publication-title: J Cancer doi: 10.7150/jca.63003 – volume: 3 year: 2013 ident: B30 article-title: The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG publication-title: EJNMMI Res doi: 10.1186/2191-219X-3-77 – volume: 12 year: 2017 ident: B10 article-title: Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer publication-title: PloS One doi: 10.1371/journal.pone.0186192 – volume: 12 year: 2020 ident: B15 article-title: Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer publication-title: J Thoracic Dis doi: 10.21037/jtd.2020.04.45 – year: 2020 ident: B22 article-title: 18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer publication-title: Ann Nucl Med doi: 10.1007/s12149-020-01451-0 – volume: 47 year: 2020 ident: B35 article-title: New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer publication-title: Eur J Nucl Med Mol I doi: 10.1007/s00259-019-04500-7 – volume: 41 year: 2020 ident: B23 article-title: Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma publication-title: Nucl Med Commun doi: 10.1097/MNM.0000000000001136 – volume: 9 year: 2022 ident: B31 article-title: Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer publication-title: Front Med doi: 10.3389/fmed.2022.895401 – volume: 45 start-page: 56 year: 2018 ident: B37 article-title: Metabolic activity by 18F– FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC publication-title: Eur J Nucl Med Mol I doi: 10.1007/s00259-017-3806-1 – volume: 37 year: 2017 ident: B11 article-title: Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer publication-title: Anticancer Res doi: 10.21873/anticanres.11813 – volume-title: TECENTRIQ ® (Atezolizumab)—EMA/234492/2021 EMEA/H/C/004143 year: 2021 ident: B8 – volume: 387 year: 2016 ident: B1 article-title: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00587-0 – volume: 35 year: 2022 ident: B18 article-title: Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer publication-title: Mod Pathol doi: 10.1038/s41379-021-00903-w – volume: 12 year: 2020 ident: B42 article-title: PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT publication-title: Cancer Manage Res doi: 10.2147/CMAR.S256871 – volume: 59 start-page: 3 year: 2018 ident: B20 article-title: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care publication-title: J Nuclear Med (1978) doi: 10.2967/jnumed.116.184028 – volume: 6 year: 2017 ident: B28 article-title: Metabolic characteristics of programmed cell death - ligand 1 - expressing lung cancer on 18F fluorodeoxyglucose positron emission tomography/computed tomography publication-title: Cancer Med doi: 10.1002/cam4.1215 |
| SSID | ssj0000650103 |
| Score | 2.3804076 |
| Snippet | Total-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for assessing... IntroductionTotal-body positron emission tomography/computed tomography (PET/CT) using uEXPLORER scanners demonstrates superior imaging capabilities for... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1578419 |
| SubjectTerms | immunotherapy NSCLC Oncology PD-L1 prognosis SUR |
| Title | The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40672750 https://www.proquest.com/docview/3230913041 https://pubmed.ncbi.nlm.nih.gov/PMC12263409 https://doaj.org/article/fcf12c866fd642c594ee2a028d3bd5ca |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfBtflOBJiJN-pnPUdddFVPYwC3ML6RcOjJ1lZhbcuz_cqiSzzIjgxUtIuhtS9FeprkpXf8XYG22jjrWuS288BigpitJ1yeKdc7aSQXdhYPv8Zs4u1OeFXuyV-qKcsJEeeJy4WfKJC2-NSQFdZa8bFaPocFUM0gXtB9cI17y9YGq0wZoKGIzbmBiFNbPUZ2IsFPod17TX1hwsRANf_9-czD9zJfcWn9N77O7kNcL7Udr77FbMD9jtr9O--EP2C9GGyzU9k_kCovCO0CfY9uhcg-vDNZyfzGfHc1hmIIpiOP9YfuEQf06JsBm6HGBJp0WmM1nXNHSXIgC5z-XmR7daAf3qhxXaCPDUtYaJmnXziF2cnsyPz8qpvkLppbLbshGJJ_IYQ7Q8YqyEdruOXoRUe9FJ6VQUxglubDKpEdjUWJ9io3gIXa2VfMyO8O3xKQPjKiqk1HnrK-UCWvMohUzK-2RirVzB3u4mu70caTRaDD8ImZaQaQmZdkKmYB8IjpuBxIA9NKBetJNetP_Si4K93oHZ4hdDc9Pl2F9tWhSMyFArxQv2ZAT35lVq2JnWVcHsAewHshz25OX3gZWboyMrMVp-9j-kf87u0IwMecHiBTvarq_iS_R-tu7VoOh4_bTgvwGOYQfX |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+predictive+value+of+total+body+PET%2FCT+in+high+PD-L1+expression+and+immunotherapy+in+advanced+non-small+cell+lung+cancer+patients&rft.jtitle=Frontiers+in+oncology&rft.au=Huibin+Jin&rft.au=Huibin+Jin&rft.au=Bingxin+Hu&rft.au=Bingxin+Hu&rft.date=2025-07-02&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=15&rft_id=info:doi/10.3389%2Ffonc.2025.1578419&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_fcf12c866fd642c594ee2a028d3bd5ca |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |